Trial Profile
A Study to Compare the Severe Vascular Events and other Non-Hematological Complications in Patients With Chronic Myeloid Leukemia Treated With Dasatinib or Nilotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 28 Apr 2016 New trial record